Arca
Skip to content
Tools
Tools

AKR1B1: Aldo-keto reductase family 1 member B1

Catalyzes the NADPH-dependent reduction of a wide variety of carbonyl-containing compounds to their corresponding alcohols.

  • Drugs that act on it: 4
  • Approved: 2
  • In phases 1 to 3: 2
  • Sponsors: 2

Who is on it, and how far along

Every drug ChEMBL records acting on AKR1B1, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 4

Approved2

  • Epalrestat
  • Tolrestat

Phase 32

  • Caficrestat
  • Sorbinil

Phase 20

    Phase 10

      Sponsors

      Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

      • Arctic Therapeutics125%
      • NeuromaxBionevia125%

      The landscape

      Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: Aldose reductase inhibitor.
      EpalrestatApprovedNeuromaxBioneviaSmall moleculeInhibitor3
      TolrestatWithdrawnApproved—Small moleculeInhibitor0
      CaficrestatPhase 3Arctic TherapeuticsSmall moleculeInhibitor2
      SorbinilPhase 3—Small moleculeInhibitor0

      Open trials

      The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 5 in all, from ClinicalTrials.gov.
      Safety, Tolerability and Efficacy of NPI-001 in Patients With Hereditary Cystatin C Amyloid Angiopathy (HCCAA)CaficrestatPhase 2Active, not recruitingArctic TherapeuticsJul 21, 2026
      Epalrestat Combined With HAIC, Donafenib and Tislelizumab as First-line Treatment for Patients With Unresectable HCC and DiabetesEpalrestatPhase 2RecruitingHaibo ShaoApr 30, 2026
      Different Amounts of Moxibustion in the Treatment of DPN: A Clinical RCT StudyEpalrestatNot applicableActive, not recruitingZhejiang Chinese Medical UniversityMar 26, 2024
      Evaluating a Nitric Oxide Generator, Nebivolol as a Disease Modifier in Patients With Diabetic Neuropathy.EpalrestatPhase 2 / Phase 3RecruitingSt. John's Research InstituteJan 11, 2024
      Safety and Efficacy of AT-001 in Patients With Diabetic CardiomyopathyCaficrestatPhase 3Active, not recruitingApplied Therapeutics, Inc.Sep 10, 2019

      Diseases most associated with it

      Open Targets association score, 0 to 1; all associations

      Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL1900, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt P15121, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

      Esc

      Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

      Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.